SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2021 / Cilt: 5 - Sayı: 2

Could Systemic Inflammation-Based Prognostic ScoresPredict the Clinical Outcome in Patients with Breast CancerTreated with Everolimus Plus Exemestane?

Nebi Serkan DEMİRCİ
Mehmet KARADAĞ
Fuat Hulusi DEMİRELLİ
Emir ÇELİK
Nilay Sengul SAMANCI
Pages
225–231
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Median PFS was 8.9 months and median overall survival (OS) was31.8 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breastcancer (mBC) patients who received everolimus plus exemestane.
📊
Key Findings & Data:Results: A total of 80 mBC patients were included.
💡
Conclusion & Impact:Median PFS was 8.9 months and median overall survival (OS) was31.8 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: No study to clarify which inflammation score could best reflect survival in a cohort of metastatic breastcancer (mBC) patients who received everolimus plus exemestane. Methods: The impact of neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and prognostic nutritional index (PNI) on PFS and OS was evaluated. Results: A total of 80 mBC patients were included. Median PFS was 8.9 months and median overall survival (OS) was31.8 months. We found that there was no significant difference between NLR, PLR, SII, and PNI groups for median PFSand OS. Conclusion: Inflammation-based prognostic scores were not correlated with prognosis in patients with mBC who hadbeen treated with everolimus plus exemestane.

🔖

Cite This Article

DEMİRCİ, N. S., KARADAĞ, M., DEMİRELLİ, F. H., ÇELİK, E., SAMANCI, N. S. (2022). Could Systemic Inflammation-Based Prognostic ScoresPredict the Clinical Outcome in Patients with Breast CancerTreated with Everolimus Plus Exemestane?. Eurasian Journal of Medical Investigation, Cilt: 5 - Sayı: 2, 225–231. https://ajindex.com/articles/508580

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012; 2012. Available at: http://globocan.iarc.fr/ Default.aspx. Accessed Dec 1, 2019
  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34
  3. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106:dju055
  4. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 2011;62:233–47
  5. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormonereceptor–positive advanced breast cancer. N Engl J Med 2012;366:520–9
  6. Liu J, Lin PC, Zhou BP. Inflammation fuels tumor progress and metastasis. Curr Pharm Des 2015;21:3032–40
  7. Mirili C, Yılmaz A, Demirkan S, Bilici M, Basol Tekin S. Clinical significance of prognostic nutritional index (PNI) in malignant melanoma. Int J Clin Oncol 2019;24:1301–10
  8. Demirci NS, Erdem GU. Prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with operable ampullary carcinoma. Bosn J Basic Med Sci 2018;18:268–74
  9. Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F, et al. Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone. Front Pharmacol 2016;7:376
  10. Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 2013;109:1755–9
  11. Wang J, Yu B, Ye Y, Shen J, Ding N, Tang H, et al. Predictive value of nutritional risk screening 2002 and prognostic nutritional index for esophageal cancer patients undergoing definitive radiochemotherapy. Nutr Cancer 2018;70:879–85
  12. Duan J, Pan L, Yang M. Preoperative elevated neutrophil-tolymphocyte ratio (NLR) and derived NLR are associated with poor prognosis in patients with breast cancer: A meta-analysis. Medicine 2018;97:e13340
  13. Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol 2015;12:584–96
  14. Rashid F, Waraich N, Bhatti I, Saha S, Khan RN, Ahmed J, et al. A pre-operative elevated neutrophil: lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Onc 2010;8:1
  15. Lee S,